Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions

Area of Science:

• Oncology
• Pharmacology
• Biomedical Engineering

Background:

• Fibroblast activation protein (FAP) is a promising target for cancer therapy and diagnostics.
• FAP-targeted interventions are increasingly being explored in clinical settings.
• Understanding the current landscape of FAP-targeted clinical trials is crucial for future development.

Purpose of the Study:

• To review the current status of fibroblast activation protein (FAP)-targeted interventions.
• To analyze data from clinicaltrials.gov regarding FAP-targeted studies.
• To identify trends and the stage of development for FAP-targeted therapies and imaging agents.

Main Methods:

• Systematic review of clinical trial data from clinicaltrials.gov.
• Analysis of 37 reviewed records focusing on FAP-targeted interventions.
• Categorization of studies into imaging, non-radioligand therapy, and radioligand therapy.

Main Results:

• Imaging studies represent the largest proportion of active FAP-targeted clinical studies.
• Therapeutic studies, including non-radioligand and radioligand therapy, are also progressing.
• The field of FAP-targeted interventions is in its early stages but shows significant growth.

Conclusions:

• Current FAP-targeted interventions are primarily in early clinical development.
• The momentum in this field suggests potential for significant future clinical applications.
• Further clinical studies are essential to determine the utility and guide the development of FAP-targeted agents.